AEZS has lost countless millions ( any idea how much?) over the years trying to get approval for drugs in its pipeline. If purchased, do these losses transfer to the buyer with considerable tax savings? If so, besides acquiring a drug with retail value there should be considerable tax advantages reducing the actual cost to buyer. True?
0 for 2 for this very long, hoping company can go 1/3 and learned from previous mistakes in phase 3 trials
been investor in this company unfortunately longer than can remember; previous phase 3 studies on BPH and colon cancer failed miserably and unexpectedly and in retrospect the phase 2 studies did not have enough patients enrolled and also failed with growth hormone. So, AEZS has very poor track record (apparently not uncommon in late phase studies among biotechs). For those that are better at evaluating the structure of these studies, did they learn anything from their previous failures? Did they have enough enrolled in phase 2 to be reliable indicator for phase 3? Structured properly to meet scrutiny of FDA?
And we all know if the results are poor what we can expect of the stock price but what if the results are positive, encouraging ( mildly? very good?) what about the stock price? results released when?
Then what to expect from ovarian? prostate and other trials: